Ditch Labs Inc. Acquires Enovap SAS, Expanding its Footprint in the Global Nicotine Addiction Market
Montreal, Canada – December 7, 2023 – Ditch Labs Inc., a leading innovator in the field of nicotine addiction treatment, today announced the strategic acquisition of key assets from Enovap SAS, a French company known for its advanced nicotine delivery solutions. This acquisition marks a significant step in Ditch Labs’ journey to reshape the landscape of nicotine addiction treatments.
The acquisition of a comprehensive portfolio of patents from Enovap SAS, granted in 15 countries, significantly enhances Ditch Labs' intellectual property holdings and positions the company as a key innovator in the inhalation and respiratory sector. This strategic move goes beyond addressing nicotine addiction, expanding Ditch Labs' reach in developing advanced inhalation technologies. Moreover, this expansion not only strengthens Ditch Labs’ role in the nicotine addiction treatment market valued at $40 billion but also unlocks opportunities for licensing and strategic partnerships, essential for driving forward innovation in healthcare solutions on a global scale.
Laurent Laferriere, CEO of Ditch Labs, shared his enthusiasm for the acquisition: "This acquisition from Enovap is a testament to our commitment to being at the forefront of innovation in the nicotine addiction treatment space. By integrating these key assets, we are ready to expand our reach and deliver cutting-edge solutions that cater to the unique needs of individuals battling nicotine addiction."
Ditch Labs' approach to nicotine addiction treatment uniquely combines a smart medical nicotine vaporizer with a comprehensive therapeutic mobile app. This integrated solution aims to revolutionize the treatment landscape by offering a more effective and personalized approach to smoking cessation and nicotine dependence.
The cost of the acquisition remains undisclosed.